John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.

Articles by John Carroll

New poll taps strong public fear about HIV vaccines

One of the biggest problems vaccine manufacturers now face is the deeply ingrained fear that a vaccine will give you the very disease it's designed to guard against. And that fear was evident in a

New therapeutic vax targets multiple cancers

Investigators are reporting promising results from their early-stage trial of a new therapeutic cancer vaccine. Scientists say the new vaccine uses an alphavirus to deliver a gene for the

Dendreon: Provenge on course to hit blockbuster goal

In the first three months following the FDA's approval of the revolutionary new prostate cancer vaccine Provenge, Dendreon was able to gin a mere $2.8 million in sales as it began to ramp up

Biovest wins orphan drug status for cancer vax

Biovest International has announced that the FDA has granted orphan drug designation to BiovaxID, its personalized cancer vaccine, for a second lymphoma indication. "With promising clinical trials

Merck, Sanofi outline plans for new animal health JV

The newly created Merial-Intervet is being forged by Merck and Sanofi-Aventis into a global powerhouse in the animal health industry, and it will rely heavily on income from some best-selling

NEJM lays out questions--and facts--about Provenge

Shares of Dendreon (NASDAQ: DNDN) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly started tumbling fast as all sorts of questions arose about supply issues and

Vax nanopatch offers stick-on alternative to a needle

During the next pandemic, people may be able to get their vaccines delivered in the mail rather than having to wait in line for a jab. Prof. Mark Kendall of the Australian Institute for Biotechnology

Project BioShield's vax programs on the chopping block

When Congress created Project BioShield four years ago, lawmakers believed that offering developers contracts guaranteeing the acquisition of new vaccines and drugs would spur the biotech industry to

Computer scientist engineers tame type of live vax

A computer scientist at the University of Miami has collaborated with scientists at Stony Brook University to design new and better vaccines that can knock out a virus while laying to rest some of

Smallpox vaccinia virus spread by physical contact

For the fifth time in the past year, a woman who had sexual contact with a member of the U.S. military contracted the vaccinia virus after being exposed to the puncture site for a smallpox vaccine.